Concepts (111)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Autoantibodies | 2 | 2025 | 483 | 1.250 |
Why?
|
| Pseudotumor Cerebri | 3 | 2021 | 14 | 1.020 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2025 | 16 | 0.950 |
Why?
|
| Optic Neuritis | 1 | 2025 | 14 | 0.950 |
Why?
|
| Ophthalmologic Surgical Procedures | 3 | 2021 | 24 | 0.910 |
Why?
|
| Disease Management | 1 | 2025 | 91 | 0.900 |
Why?
|
| Optic Nerve | 2 | 2021 | 28 | 0.850 |
Why?
|
| Nystagmus, Pathologic | 1 | 2023 | 4 | 0.800 |
Why?
|
| Deglutition Disorders | 1 | 2023 | 24 | 0.780 |
Why?
|
| Amblyopia | 1 | 2021 | 6 | 0.710 |
Why?
|
| Optic Nerve Diseases | 1 | 2021 | 16 | 0.710 |
Why?
|
| Hamartoma | 1 | 2021 | 13 | 0.700 |
Why?
|
| Exanthema | 1 | 2021 | 14 | 0.700 |
Why?
|
| Conjunctiva | 1 | 2021 | 14 | 0.680 |
Why?
|
| Eye Diseases | 1 | 2021 | 31 | 0.670 |
Why?
|
| Receptors, Cholinergic | 1 | 2020 | 4 | 0.640 |
Why?
|
| Myasthenia Gravis | 1 | 2020 | 3 | 0.640 |
Why?
|
| Decompression, Surgical | 1 | 2021 | 81 | 0.640 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2020 | 51 | 0.610 |
Why?
|
| Vision Disorders | 3 | 2021 | 38 | 0.510 |
Why?
|
| Humans | 18 | 2025 | 28998 | 0.390 |
Why?
|
| Pupil Disorders | 1 | 2011 | 1 | 0.350 |
Why?
|
| Iris Diseases | 1 | 2011 | 2 | 0.350 |
Why?
|
| Membranes | 1 | 2011 | 8 | 0.350 |
Why?
|
| Intraoperative Complications | 1 | 2011 | 47 | 0.330 |
Why?
|
| Tomography, Optical Coherence | 2 | 2025 | 96 | 0.270 |
Why?
|
| Visual Acuity | 3 | 2025 | 119 | 0.260 |
Why?
|
| Male | 10 | 2025 | 13983 | 0.250 |
Why?
|
| Neuromyelitis Optica | 1 | 2025 | 9 | 0.240 |
Why?
|
| Vitamin A Deficiency | 1 | 2025 | 13 | 0.230 |
Why?
|
| Corneal Diseases | 1 | 2025 | 25 | 0.230 |
Why?
|
| Visual Fields | 2 | 2021 | 35 | 0.210 |
Why?
|
| Health Literacy | 2 | 2014 | 34 | 0.200 |
Why?
|
| Adult | 6 | 2021 | 8048 | 0.200 |
Why?
|
| Child, Preschool | 3 | 2025 | 1196 | 0.200 |
Why?
|
| Educational Measurement | 2 | 2014 | 139 | 0.190 |
Why?
|
| Retrospective Studies | 5 | 2022 | 2644 | 0.190 |
Why?
|
| Emergency Service, Hospital | 2 | 2014 | 123 | 0.190 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2022 | 3 | 0.190 |
Why?
|
| Optic Disk | 1 | 2022 | 10 | 0.190 |
Why?
|
| Young Adult | 5 | 2021 | 2842 | 0.180 |
Why?
|
| Blindness | 1 | 2021 | 34 | 0.180 |
Why?
|
| Eye Injuries | 1 | 2021 | 11 | 0.170 |
Why?
|
| Spinal Puncture | 1 | 2021 | 11 | 0.170 |
Why?
|
| Intracranial Pressure | 1 | 2021 | 12 | 0.170 |
Why?
|
| Emergencies | 1 | 2021 | 28 | 0.170 |
Why?
|
| Visual Field Tests | 1 | 2021 | 16 | 0.170 |
Why?
|
| Nose | 1 | 2021 | 24 | 0.170 |
Why?
|
| Papilledema | 1 | 2020 | 8 | 0.170 |
Why?
|
| Treatment Outcome | 4 | 2021 | 2427 | 0.160 |
Why?
|
| Mass Screening | 1 | 2021 | 159 | 0.150 |
Why?
|
| Adolescent | 4 | 2021 | 3223 | 0.150 |
Why?
|
| Primary Health Care | 1 | 2021 | 169 | 0.150 |
Why?
|
| Orbital Implants | 1 | 2019 | 4 | 0.150 |
Why?
|
| Polyethylene | 1 | 2019 | 12 | 0.150 |
Why?
|
| Middle Aged | 6 | 2021 | 7428 | 0.150 |
Why?
|
| Prosthesis Implantation | 1 | 2019 | 26 | 0.150 |
Why?
|
| Fracture Fixation | 1 | 2019 | 17 | 0.150 |
Why?
|
| Female | 9 | 2021 | 15690 | 0.140 |
Why?
|
| Child | 3 | 2021 | 2327 | 0.140 |
Why?
|
| Disease Progression | 1 | 2020 | 479 | 0.140 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2019 | 72 | 0.140 |
Why?
|
| Prognosis | 1 | 2020 | 812 | 0.130 |
Why?
|
| Mathematical Concepts | 2 | 2014 | 11 | 0.130 |
Why?
|
| Blepharoplasty | 1 | 2016 | 3 | 0.120 |
Why?
|
| Eyelid Diseases | 1 | 2016 | 7 | 0.120 |
Why?
|
| Brain | 1 | 2021 | 770 | 0.120 |
Why?
|
| Syndrome | 2 | 2016 | 79 | 0.120 |
Why?
|
| Drug Therapy, Combination | 2 | 2011 | 210 | 0.100 |
Why?
|
| Esotropia | 1 | 2012 | 6 | 0.090 |
Why?
|
| Oculomotor Muscles | 1 | 2012 | 18 | 0.090 |
Why?
|
| Down Syndrome | 1 | 2012 | 20 | 0.090 |
Why?
|
| Miotics | 1 | 2011 | 1 | 0.090 |
Why?
|
| Mydriatics | 1 | 2011 | 6 | 0.090 |
Why?
|
| Pilocarpine | 1 | 2011 | 8 | 0.090 |
Why?
|
| Phenylephrine | 1 | 2011 | 14 | 0.090 |
Why?
|
| Eye Infections, Fungal | 1 | 2011 | 5 | 0.090 |
Why?
|
| Mitosporic Fungi | 1 | 2011 | 2 | 0.090 |
Why?
|
| Mycoses | 1 | 2011 | 9 | 0.090 |
Why?
|
| Corneal Ulcer | 1 | 2011 | 12 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 2067 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2019 | 1283 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2011 | 924 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2022 | 739 | 0.060 |
Why?
|
| Aged | 4 | 2019 | 5608 | 0.060 |
Why?
|
| Vitamin A | 1 | 2025 | 32 | 0.060 |
Why?
|
| Urban Health Services | 2 | 2014 | 9 | 0.050 |
Why?
|
| Language | 2 | 2014 | 66 | 0.050 |
Why?
|
| Retinal Ganglion Cells | 1 | 2022 | 26 | 0.050 |
Why?
|
| Time Factors | 2 | 2019 | 1619 | 0.050 |
Why?
|
| Demography | 1 | 2022 | 94 | 0.050 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 2020 | 2 | 0.040 |
Why?
|
| Headache | 1 | 2020 | 35 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 1004 | 0.040 |
Why?
|
| Orbital Fractures | 1 | 2019 | 6 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 470 | 0.040 |
Why?
|
| Porosity | 1 | 2019 | 38 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2020 | 415 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2019 | 88 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2021 | 898 | 0.040 |
Why?
|
| Risk Factors | 1 | 2022 | 2134 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 1032 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 27 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 40 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 144 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2014 | 225 | 0.020 |
Why?
|
| Vision, Binocular | 1 | 2012 | 8 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 68 | 0.020 |
Why?
|
| Contact Lenses, Hydrophilic | 1 | 2011 | 2 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2011 | 69 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 1011 | 0.020 |
Why?
|